These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
125 related articles for article (PubMed ID: 14556608)
1. Assuring the benefits of modern medicine for all Americans. Woodcock J Healthplan; 2003; 44(5):23-6. PubMed ID: 14556608 [No Abstract] [Full Text] [Related]
2. The role of the pharmaceutical industry in disseminating pharmacovigilance practice in developing countries. Shani S; Yahalom Z Food Drug Law J; 2008; 63(3):701-11. PubMed ID: 19031669 [No Abstract] [Full Text] [Related]
3. Risk management and intrusions on medical practice: striking a balance. Enzi MB; Kennedy EM Health Aff (Millwood); 2007; 26(3):678-80. PubMed ID: 17485743 [TBL] [Abstract][Full Text] [Related]
4. The unfinished business of U.S. drug safety regulation. Evans BJ; Flockhart DA Food Drug Law J; 2006; 61(1):45-63. PubMed ID: 16838457 [No Abstract] [Full Text] [Related]
5. FDA approvals of old drugs put new pressure on payers. Silverman E Manag Care; 2011 May; 20(5):30-1. PubMed ID: 21667624 [No Abstract] [Full Text] [Related]
6. A precarious balancing act--the role of the FDA as protector of public health and industry wealth. McCabe AR Suffolk Univ Law Rev; 2003; 36(3):787-819. PubMed ID: 16493844 [No Abstract] [Full Text] [Related]
7. Drug approval and pharmaceutical pricing. Kozma CM Manag Care Interface; 2002 Feb; 15(2):65-6. PubMed ID: 11875964 [No Abstract] [Full Text] [Related]
8. Bush tails follow-ons. Fox J Nat Biotechnol; 2008 Apr; 26(4):366. PubMed ID: 18392007 [No Abstract] [Full Text] [Related]
9. FDA embraces risk-management approach. Fox JL Nat Biotechnol; 2003 Oct; 21(10):1120-1. PubMed ID: 14520383 [No Abstract] [Full Text] [Related]
10. FDA to steer nanotech. Fox JL Nat Biotechnol; 2008 Oct; 26(10):1060. PubMed ID: 18846060 [No Abstract] [Full Text] [Related]
11. Drug review "behind the curtain": a response to Professor Struve. O'Reilly JT Cornell Law Rev; 2008 Jul; 93(5):1075-90. PubMed ID: 18618971 [No Abstract] [Full Text] [Related]
12. Drug and vaccine development for infectious diseases: the value of priority review vouchers. Matheny J; Smith B; Courtney B; Mair M Clin Pharmacol Ther; 2009 Jun; 85(6):571-2. PubMed ID: 19451907 [No Abstract] [Full Text] [Related]
13. The federal preemption debate in pharmaceutical labeling product liability actions. Gross JM; Curry JA Tort Trial Insur Pract Law J; 2007; 43(1):35-70. PubMed ID: 18354866 [No Abstract] [Full Text] [Related]
14. Priority review vouchers: an inefficient and dangerous way to promote neglected-disease drug development. Kesselheim AS Clin Pharmacol Ther; 2009 Jun; 85(6):573-5. PubMed ID: 19451908 [No Abstract] [Full Text] [Related]
15. Drug safety: a contrarian's point of view. Cobert B Food Drug Law J; 2007; 62(3):501-12. PubMed ID: 17915392 [No Abstract] [Full Text] [Related]
16. 2009 FDA drug approvals. Hughes B Nat Rev Drug Discov; 2010 Feb; 9(2):89-92. PubMed ID: 20118952 [No Abstract] [Full Text] [Related]
17. The Rx-to-OTC switch of Claritin, Allegra, and Zyrtec: an unprecedented FDA response to petitioners and the protection of public health. Spencer HM Am Univ Law Rev; 2002 Jun; 51(5):999-1050. PubMed ID: 12197546 [No Abstract] [Full Text] [Related]
18. The challenges of globalization in pharmaceutical law--is an international drug approval system modeled after the European system worth considering? Purnhagen KP Food Drug Law J; 2008; 63(3):623-45. PubMed ID: 19031663 [No Abstract] [Full Text] [Related]